Navigation Links
Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis

WOODCLIFF LAKE, N.J., Dec. 22 /PRNewswire/ -- The investigational compound, eritoran tetrasodium ("eritoran," also known as E5564) appeared to be well tolerated in patients with severe sepsis in a Phase II trial published in the January issue of Critical Care Medicine, the official journal of the Society of Critical Care Medicine, the largest multiprofessional organization dedicated to ensuring excellence and consistency in the practice of critical care.

The trial evaluated two doses of eritoran, low-dose (45mg given every 12 hours for six days) and high-dose (105mg given every 12 hours for six days), along with a placebo group. Additionally, the trial, although not powered for statistical significance, evaluated the efficacy (reduction in 28-day all-cause mortality) of eritoran versus placebo.

"Currently, limited treatment options exist for severe sepsis. In this Phase II study, eritoran was well tolerated, and the adverse events were not surprising, given the significant co-morbidities commonly seen in patients with severe sepsis," said lead investigator Mark Tidswell, MD, Director, ICU Research, Baystate Medical Center, Adult Critical Care Division, in Springfield, Mass. "Although this Phase II trial was not sized to demonstrate a reduction in mortality and the observed 26.6% mortality rate for high-dose eritoran versus 33.3% for placebo (p=0.34) was not statistically significant, the data warrant further investigation of eritoran."

About the Phase II Trial

This trial of eritoran tetrasodium (E5564) was a Phase II, randomized, double-blind, placebo-controlled, multi-center, ascending-dose trial evaluating the safety and efficacy of eritoran in patients with severe sepsis. The trial, conducted in intensive care units (ICUs) in the United States and Canada, involved 300 patients randomized to three groups: 96 received placebo, 103 received eritoran low-dose (45mg given every 12 hours for six days) and 94 patients received eritoran high-dose (105mg given every 12 hours for six days). Seven patients did not receive any trial drug and were not included in the modified intent to treat population for analysis. Eritoran or placebo doses were administered via intravenous infusion within 12 hours of recognition of severe sepsis and repeated every 12 hours for six days.

In this Phase II trial, eritoran was well tolerated, and the following adverse events were found:

Anemia, diarrhea, insomnia, acute renal failure and rash were observed more frequently in the group receiving eritoran compared to the group receiving placebo, although not statistically significant.

Serious adverse events that occurred in greater than 5% of patients in both the eritoran and placebo treated groups included cardiac arrest, multiorgan failure, sepsis, respiratory failure and deep vein thrombosis.

Four patients in the group receiving eritoran experienced a hepatobiliary serious adverse event compared with none in the group receiving placebo. Three of these four subjects had pre-existing liver disease.

A higher incidence of atrial fibrillation seen in the eritoran high-dose group (12.8%) compared to placebo (7.3%) was not statistically significant. Instances were mild or moderate in severity and it was unclear if the increased incidence is related to eritoran administration.

Phlebitis (inflammation of the vein) was observed in 6.7% of patients dosed with eritoran high-dose through a peripheral vein (versus 1.6% through central line); affected subjects recovered. No patient in the group receiving placebo experienced phlebitis.

The occurrence of infectious complications reported as adverse events by trial investigators did not differ notably among the three groups.

The mortality in the placebo, low-dose and high-dose groups was 33.3%, 32% and 26.6% respectively. Although not statistically significant (p=0.34), the difference in mortality between the high-dose group and placebo was 6.7%.

The greatest benefit was observed in the population at the highest risk of mortality as assessed by APACHE II Predicted Risk of Mortality (PROM). In patients who were considered at higher risk of death, mortality among placebo patients was 56.3% versus 33.3% in high-dose patients (p=0.105).


Based on the trial results, Eisai is now conducting a global Phase III clinical trial program, called ACCESS (A Controlled Comparison of Eritoran tetrasodium and Placebo in Patients with Severe Sepsis). The trial will further evaluate eritoran as a potential treatment for severe sepsis, the second most frequent cause of death in intensive care patients in the U.S., surpassed only by cardiovascular events. In the European Union (EU), sepsis is the most common cause of death in the ICU.

The ACCESS trial population will enroll substantially more patients than the Phase II trial and has been sized (n=2,000) to determine the efficacy (reduction in 28-day all-cause mortality) of eritoran and targets a population with severe sepsis that has a moderate-to-high risk of mortality as determined by baseline APACHE II (Acute Physiology and Chronic Health Evaluation II) scores from 21 to 37. APACHE II is a severity of illness scoring system commonly used in sepsis research and ICUs.

About Eritoran, TLR4 and Severe Sepsis

Sepsis is a condition involving infection and inflammation. The body's normal response to an infection is to initiate an immunological chain reaction of inflammation. In severe sepsis, systemic inflammation may be an overreaction leading to injury and failure of one or more organ systems that may become life-threatening. The toll-like receptor 4 (TLR4) is part of the innate immune system and, when it is activated, TLR4 may play an important role in the course of severe sepsis. Discovered and developed by Eisai scientists, eritoran is believed to block activation of TLR4.

More than 750,000 individuals develop severe sepsis in North America each year, with a high mortality risk of 30-35% (depending on population studied). Incidence figures in Japan are believed to be similar to those reported for North America. The incidence of severe sepsis in the European Union has been estimated at 90.4 cases per 100,000 population, with a mortality of 36%.

Eisai's research and development efforts regarding eritoran and severe sepsis exemplify the company's human health care mission, which is to address unmet medical needs and increase benefits to patients and their families.

Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina. For more information about Eisai, please visit

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

For more information regarding eritoran or ongoing clinical trials, please contact Eisai Medical Services at 1-888-274-2378.


Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
3. American Imaging Managements New Specialty Drug Program Delivers Immediate Results
4. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
5. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
6. Immucor to Announce Fiscal Second Quarter Financial Results on Wednesday, January 6, 2010
7. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
10. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is ... powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been ... pleased to be the first in Arkansas to introduce the most powerful SCS system ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of ... With the average cost of healthcare rising and the U.S. senior population expected to ... affordability of where they live. An annual 2017 report looked at a variety of ...
(Date:5/26/2017)... ... 2017 , ... via seating is proud to partner with ... specifically designed for clinical areas. Genie Copper Mesh is a crossover chair for ... provide customers with a game changing chair that is affordably priced,” Chas Hepler ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... will continue to be available at a discounted crowdfunding price on Indiegogo . ... they are, I also wanted to bring a fidget toy to the market that ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):